Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-01-16
2008-07-29
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S960000
Reexamination Certificate
active
07405223
ABSTRACT:
A method of treating and/or preventing allergic and inflammatory conditions of the skin or upper and lower airway passages, e.g. seasonal allergic rhinitis, perennial allergic rhinitis, or chronic idopathic urticaria, in a human more 12 years old, by administering an amount of desloratadine, e.g. 2×2.5 mg or 5 mg/day for a time sufficient to produce a geometric mean steady state maximum plasma concentration of desloratadine in the range of about 2.90 ng/mL to about 4.54 ng/mL, or a arithmetic mean steady state maximum plasma concentration of desloratadine in the range of about 3.2 ng/mL to about 5.0 ng/mL is disclosed.
REFERENCES:
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3940485 (1976-02-01), Levinson et al.
patent: 4008796 (1977-02-01), Aylon
patent: 4282233 (1981-08-01), Vilani
patent: 4371516 (1983-02-01), Gregory et al.
patent: 4552899 (1985-11-01), Sunshine et al.
patent: 4659716 (1987-04-01), Villani et al.
patent: 4731447 (1988-03-01), Schumacher et al.
patent: 4777170 (1988-10-01), Heinrich
patent: 4783465 (1988-11-01), Sunshine et al.
patent: 4804666 (1989-02-01), Piwinski et al.
patent: 4863931 (1989-09-01), Schumacher et al.
patent: 4906647 (1990-03-01), Kouchiwa et al.
patent: 4990535 (1991-02-01), Cho et al.
patent: 5019591 (1991-05-01), Gardner et al.
patent: 5089496 (1992-02-01), Piwinski et al.
patent: 5100675 (1992-03-01), Cho et al.
patent: 5314697 (1994-05-01), Kwan et al.
patent: 5407941 (1995-04-01), Carceller et al.
patent: 5476856 (1995-12-01), Carceller et al.
patent: 5502080 (1996-03-01), Hitzig
patent: 5595997 (1997-01-01), Aberg et al.
patent: 5698558 (1997-12-01), Gray
patent: 5731319 (1998-03-01), Aberg et al.
patent: 5900421 (1999-05-01), Handley et al.
patent: 5939426 (1999-08-01), McCullough
patent: 5962464 (1999-10-01), Handley et al.
patent: 6051585 (2000-04-01), Weinstein et al.
patent: 6054463 (2000-04-01), Handley et al.
patent: 6100274 (2000-08-01), Kou
patent: 6114346 (2000-09-01), Harris et al.
patent: 6132758 (2000-10-01), Munayyer et al.
patent: 6265414 (2001-07-01), Harris et al.
patent: 6270796 (2001-08-01), Weinstein
patent: 6423721 (2002-07-01), Harris et al.
patent: 6432972 (2002-08-01), Salmun et al.
patent: 6506767 (2003-01-01), Schumacher et al.
patent: 6514520 (2003-02-01), Munayyer et al.
patent: 6521254 (2003-02-01), Weinstein et al.
patent: 6599913 (2003-07-01), Johnson et al.
patent: 2003/0004179 (2003-01-01), Affrime et al.
patent: 0 264 259 (1988-04-01), None
patent: 0 288640 (1988-11-01), None
patent: 0 396404 (1990-11-01), None
patent: 0 577 957 (1994-01-01), None
patent: 0 396404 (1994-02-01), None
patent: WO 85/03707 (1985-08-01), None
patent: WO 92/00293 (1992-01-01), None
patent: WO 92/11034 (1992-07-01), None
patent: WO 92/20377 (1992-11-01), None
patent: WO 96/16641 (1996-06-01), None
patent: WO 96/20708 (1996-07-01), None
patent: WO 98/34614 (1998-08-01), None
patent: WO 99/32125 (1999-07-01), None
patent: WO 00/02560 (2000-01-01), None
patent: WO 01/21161 (2001-03-01), None
patent: WO 01/21162 (2001-03-01), None
Dipiro et al., Pharmacotherapy A Pathophysiologic Approach, New York, (1989), Chapter 65, pp. 945-953.
Goodman & Gilman's, The Pharmacological Basis of Therapeutics, Ninth Edition, McGraw-Hill, New York, (1996), Chapter 50, p. 1192.
W. Kreutner, et al.,Preclinical Efficacy and Antiallergic Profile of Desloratadine, a Selective and Nonsedating Histamine H1-Receptor Antagonist(Abstract 1118), J. Allergy Clin. Immunol., vol. 105, No. 1, part 2, pp. S382-S383 (Jan. 2000).
L. M. Salmun, et al.,Efficacy and Safety of Desloratadine in Seasonal Allergic Rhinitis(Abstract 1123), J. Allergy Clin. Immunol., vol. 105, No. 1, part 2, pp. S384-S385 (Jan. 2000).
D. Padhi, et al.,Multiple-Dose Pharmacokinetics, Safety, and Tolerance of Desloratadine in Healthy Volunteers(Abstract 1124), J. Allergy Clin. Immunol., vol. 105, No. 1, part 2, pp. S385 (Jan. 2000).
J. M. Herron, et al.,Dose-Proportionality, Linearity, and Pharmacokinetics of Desloratadine in Healthy Volunteers(Abstract 1126), J. Allergy Clin. Immunol., vol. 105, No. 1, part 2, pp. S385 (Jan. 2000).
Andersen, et al., “Adverse drug interactions clinically important for the dermatologist”, Arch Dermatol, Apr. 1995, vol. 131, pp. 468-473.
Babe, et al., “Histamine, Bradykinn, and their Antagonists” in The Pharmacological Basis of Therapeutics (9thedition), The McGraw-Hill Co. Inc., pp. 581-599 (1996).
Barnett, et al.,“Pharmacology of Non-Sedating H 1 Antihistamines”,New Perspectives in Histamine Research, Birkhauser Verlag Basel, pp. 181-196 (1991).
Berge, et al., “Pharmaceutical Salts”, J. of Pharm. Sciences, Jan. 1977, vol. 66, No. 1, pp. 1-19.
Berthon, et al., “In Vitro inhibition, by loratadine and descarboxyethoxyloratadine, of histamine release from human basophils, and of histamine release and intracellular calcium fluxes in rat basophilic leukemia cells (RBL-2H3)”, Biochem. Pharm., 1994, vol. 47, No. 5, pp. 789-794.
Blaug, et al., “Interaction of dextroamphetamine sulfate with spray-dried lactose”, J. of Pharm. Sciences, Nov. 1972, vol. 61, No. 11, pp. 1770-1775.
Brandes, et al., “Enhanced cancer growth in mice administered daily human-equivalent doses of some H1-antihistamines: predictive in vitro correlates”, J. of the National Cancer Inst., May 18, 1994, vol. 86, No. 10, pp. 770-775.
Brandes, et al., “Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses”, Cancer Research, Jul. 1, 1992, vol. 52, pp. 3796-3800.
Brion, et al., “Evaluation of the antimuscarinic activity of atropine, terfenadine and mequitazine in healthy volunteers”, Br. J. Clin. Pharmac. 1988, vol. 25, pp. 27-32.
Carmeliet, “Voltage- and Time-Dependent Block of the Delayed K'0 Current in Cardiac Myocytes by Dofetilide”, The J. of Pharm. And Experimental Therapeutics, 1992, vol. 262, No. 2, pp. 809-817.
Castello, et al., “Discoloration of tablets containing amines and lactose”, J. of Pharm. Sciences, Feb. 1962,vol. 51, No. 2, pp. 106-108.
Cheung, et al., “Investigation of anti-motion sickness drugs in the squirrel monkey”, J. Clin. Pharmacol, 1992, vol. No. 32, pp. 163-175.
Clissold, et al., “Loratadine: A preliminary review of its pharmacodynamic properties and therapeutic efficacy”, Drugs, 1989,vol. 37, pp. 42-57.
Cooke, “Glycopyrrolate in bladder dysfunction”, SA Medical Journal, Jan. 1, 1983, p. 3.
Craft, “Torsade de pointes after astemizole overdose”, Br. Medical Journal, 1986,, vol. 292, p. 660.
Dorje, et al., “Antagonist Binding Profiles of Five Cloned Human Muscarinic Receptor Subtypes”, The J. of Pharm. And Experimental Therapeutics, 1991, vol. 256, pp. 727-733.
Drug Facts and Comparisons, 1998 Ed., Facts and Comparisons, St. Louis, Missouri, p. 2832.
Ebert, “Soft elastic gelatin capsules: a unique dosage form”, Pharmaceutical Technology, 1977, pp. 44-50.
Gengo, “Dilemma: Antihistamine selection: Use vs. Side effects”, U.S. Pharmacist, Nov. 1990, pp. 59-92.
Hartauer, et al., A Comparison of Diffuse Reflectance FT-IR Spectroscopy and DSC in the Characterization of a Drug-Excipient Interaction, “Drug Development and industrial Pharmacy”, 1991, vol. 17, No. 4, pp. 617-630.
Herzog, et al., “Urinary Incontinence: medical and Psychosocial Aspects”,Annual Review of Gerontology and Geriatrics, 1989, vol. 9, pp. 74-119.
Hilbert, et al., “Pharmacokinetics and Dose Proportionality of Loratadine”, J. Clin. Pharmacol. 1987, vol. 27, pp. 694-698.
Housley, et al., “Histamine and related substances influence neurotransmission of the semicircular canal”, Hearing Research, May 1, 1988, vol. 35, pp. 87-97.
Jankowski, et al., “Effect of Terfenadine on Nnasal Provocation”, Int. Arch. Allergy Imm
Affrime Melton B.
Banfield Christopher R.
Gupta Samir K.
Padhi Desmond
Jagoe Donna
Marschel Ardin
Schering Corporation
Schering-Plough Patent Group
LandOfFree
Treating allergic and inflammatory conditions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating allergic and inflammatory conditions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating allergic and inflammatory conditions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3964416